Sibiliter, the Korean startup behind pet health management solution Lifet, has raised pre-Series A bridge funding from Korea Technology Finance Corporation and AC Pathfinder. With this investment, Sibiliter’s cumulative funding has surpassed $1.39 million (2 billion KRW).

Sibiliter’s core competitive advantage lies in its proprietary AI technology that diagnoses progressive diseases in pets within three seconds using only smartphone photos. The company’s patella luxation diagnostic software achieved remarkable clinical trial results with 97.6% sensitivity and 98.8% specificity, earning Korea’s first Class 3 veterinary medical device approval. The research findings were published in Scientific Reports, a prestigious SCI-level international journal, establishing credibility in both academic and industry circles.

Currently, Lifet provides analysis services for major conditions including patella luxation, periodontal disease, obesity, and cataracts/nuclear sclerosis. The platform has exceeded 170,000 cumulative analyses and 80,000 registered members. Building on this technical foundation, Sibiliter will showcase its technology at CES 2026 in Las Vegas this January through Samsung Electronics’ C-Lab exhibition booth.

Sibiliter is diversifying its business model through API modules that integrate AI health check functionality. The company currently supplies its technology to major partners including smartphone manufacturers, home appliance companies, insurance providers, and telecommunications companies. Notably, the “Lifet Pet Insurance” product jointly launched with DB Insurance in April offers premium discounts based on AI analysis results, marking Korea’s first case of AI-driven pet insurance pricing.

Beyond AI analysis, Sibiliter is building a comprehensive pet homecare ecosystem by integrating over 1,000 personalized health products (supplements, functional foods) through commerce and pet insurance services for medical cost coverage. The company plans to expand its service range with the launch of primary skin disease analysis services in the first quarter of next year.

Kwanghyun Kim, CEO of Sibiliter, stated, “This investment validates that Sibiliter’s AI technology is driving real innovation across the pet industry, from pet insurance to commerce. In 2026, we will aggressively expand market share through strengthened partnerships with diverse industry players in the global market, establishing a new standard for pet homecare.”